 FSD Pharma CSE:HUGE, NASDAQ:HUGE Inc shared pre-clinical data, demonstrating the potentially disease-modifying effects of Lucid-MS the companys lead drug candidate for the potential treatment of multiple sclerosis MS in the animal models of MS. The Toronto-based biotech company said that based on more than a decade of research, Lucid-MS is a patented neuroprotective new chemical entity that affects protein citrullination and myelin structure, which are associated with the severity of MS lesions. 